mouse

08-Oct-2026

From Mouse Bioassays to Predictive Human Biology: Rethinking EPO Potency Testing

For decades, the pharmaceutical industry has accepted a fundamental compromise in biologics quality control: medicines developed for humans are often functionally characterized using biological systems that do not fully reproduce human physiology.

Readmore......

DART_-Human-Biology

05-Oct-2026

HUMAN BIOLOGY BEFORE HUMAN TRIALS

HUMAN BIOLOGY BEFORE HUMAN TRIALS The Next Competitive Advantage in Drug Development The industry does not have a data problem. It has a translation problem. Drug discovery has become extraordinarily sophisticated. We can characterize molecules at atomic resolution, generate enormous omics datasets, engineer increasingly precise biologics, and apply AI across discovery pipelines.
Readmore..

Can-We-Replace-Animal-Testing-A-Biotech-Founder-Faces-the-Den-Drug-Diaries-1080p-h264.00_00_04_09.Still002-768x432

08-Jun-2026

AI-enabled DART uses human microphysiological systems for non-animal drug and vaccine testing

DART is a continuously learning human simulation infrastructure Regulatory bodies are actively piloting alternative methods frameworks Pharmaceutical companies are buying cruelty-free testing systems And computational analytics is no longer theoretical — it is made operational The ecosystem is ready as Human Moment ,the science is ready, the urgency is undeniable
Readmore......

image-768x437

18-Apr-2025

Key Guidance in Adopting and Integrating Non-Animal based New Approach Methodologies

Non-animal New Approach Methodologies (NAMs) are transforming pharmaceutical and biotherapeutic research by combining human cell and tissue models with advanced computational tools. These strategies offer ethical, cost-effective, and scientifically relevant alternatives to traditional methods. NAMs are emerging as a revolutionary approach in human Readmore..

1744387416789-768x431

17-April-2025

Reimagining Drug & Vaccine Testing: The Feasibility of Animal-Free Platforms with Artificial Intelligence
Readmore......

FDA-Announces-Plan-to-Phase-Out-Animal-Testing-Requirement-for-Monoclonal-Antibodies-and-Other-Drugs-FDA-04-15-2025_02_43_PM (1)

27-Jan-2025

FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

n a landmark move, the FDA has announced plans to phase out animal testing requirements for monoclonal antibodies (mAbs) and other therapeutics, marking a significant shift in drug development. Readmore......

7 (1)

2024

Transcell’s scientific leadership confronts the challenges inherent in first-in-human trials and confidently introduces DART: Preparing for First-in-Human Trials – A Strategic Intervention

8

2023

Animal-Free Testing Strategy for Potency Assessment As Critical Quality Attribute – Digital Potency Testing – Invaluable Strategy To Support Antisera Industry

It is an animal-free technology that delivers human-relevant potency values for clinical correlation and extra benefits to antivenom producers to reduce time, effort, and resources on batch releases. Readmore..

6

2022

Transcell’s scientific leadership discusses new engagement models with the pharmaceutical and biopharmaceutical industry: New Approach Methodologies Concept – Creating a New World Order

The 21st century pharmaceutical and biotech sector has come a long way from its heritages in 19th century pharmacy, with differentiated contract testing services business models. Traditional contract research testing services that follow the outsourcing model offer low-cost options to pharma that come with advantages and disadvantages. With New Approach Methodologies (NAM) Readmore......

Frontiers-Potency-testing-of-cell-and-gene-therapy-products-02-18-2025_01_35_PM

27-Sep-2016

Potency testing of cell and gene therapy products

Potency testing of cell and gene therapy products Potency is one of the critical quality attributes of biological medicinal products Readmore......

1

27-Jan-2025

An industry perspective on the FDA Modernization Act 2.0/3.0: potential next steps for sponsors to reduce animal use in drug development

Pharmaceutical developers are encouraged to adopt the best practices of being purposefully thoughtful about the use of animals, seeking alternatives wherever possible. Readmore......

Precision-oncology-using-ex-vivo-technology-a-step-towards-individualised-cancer-care-PMC-02-18-2025_01_39_PM

26-Sep-2016

Precision oncology using ex vivo technology: a step towards individualised cancer care

Precision oncology using ex vivo technology: a step towards individualised cancer care Despite advances in cancer genomics and the increased... Readmore..

Vaccine-testing-without-animal-experiments-Article-in-German-ALTEX-Alternatives-to-animal-experimentation-02-18-2025_01_15_PM

15-September-2016

Vaccine testing without animal experiments?

Vaccines must provide effective protection against disease without any harmful side effects. Antigen purity is a crucial factor which until now has had to be tested on animals. However, recent scientific Readmore....